Anne focuses on health sciences policy projects relating to therapeutics discovery and development, clinical research, and ethics of medicine and emerging biotechnology. She currently serves as the staff lead on projects addressing physician-assisted death and ethics, equity, and emerging technology, and as a senior advisor to the Forum on Drug Discovery, Development, and Translation and a consensus study on Return of Individual-Specific Research Results Generated in Research Laboratories. She was also recently senior staff officer of a consensus study on Integrating Clinical Research Into Epidemic Response: The Ebola Experience, the study director of a consensus study on Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations, senior staff officer of a Hong Kong workshop on the Global Health Risk Framework: Research and Development of Medical Products, and senior staff officer of a consensus study on Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk.

Before joining the National Academies in April 2010, Ms. Claiborne was a practicing health care attorney in the Washington, DC office of an international law firm with a major health care practice, where she gained extensive experience working with the health care industry, including academic medical centers, research hospitals, health care purchasers, and pharmaceutical companies.

Ms. Claiborne received her bachelor of arts degree, with distinction, from Stanford University; her juris doctorate, cum laude, from Harvard Law School, where she was an editor of the Harvard Law Review; and her MPH (concentrating in health policy) from Johns Hopkins Bloomberg School of Public Health, where she was elected to the Delta Omega honorary society.